Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has received an average recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $66.6667.

RVPH has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Finally, Maxim Group downgraded Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH opened at $0.56 on Wednesday. The stock has a market capitalization of $7.41 million, a P/E ratio of -0.14 and a beta of 0.47. Reviva Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $17.20. The company’s fifty day moving average is $0.58 and its two-hundred day moving average is $2.54.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.10). Sell-side analysts predict that Reviva Pharmaceuticals will post -2.96 EPS for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in shares of Reviva Pharmaceuticals during the 2nd quarter worth $31,000. Lido Advisors LLC purchased a new stake in Reviva Pharmaceuticals during the third quarter worth about $37,000. NewEdge Advisors LLC acquired a new position in Reviva Pharmaceuticals during the first quarter worth about $58,000. State Street Corp grew its position in Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after buying an additional 256,500 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares in the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.